GC Genome Presents Clinical Applications of Early Cancer Screening Test "iCanSearch"

"2025 iCanSearch Vision Symposium" Held for Medical Professionals

GC Genome, a company specializing in liquid biopsy and clinical genomics analysis, announced that it held the "2025 iCanSearch Vision Symposium" for medical professionals at EL Tower in Seocho-gu, Seoul on the 22nd.

Kichang Seok, CEO of GC Genome, is giving a greeting at the "2025 iCanSearch Vision Symposium" held for medical staff at EL Tower in Seocho-gu, Seoul on the 22nd. GC Genome

This event was organized to share the future vision and clinical value of GC Genome's early cancer screening test, "ai-CANCERCH (iCanSearch)," with the medical field, and to discuss practical applications in real clinical settings.

Professors from major university hospitals specializing in cancer diagnosis and screening attended the symposium and presented clinical case studies on the application of the iCanSearch test. In particular, cases were introduced in which cancers that had not been detected through standard health checkups were identified early and confirmed using this test, as well as cases where the test was used as a non-invasive alternative for elderly patients who avoid endoscopy. These examples highlighted the practical utility of the test in real-world medical settings.

GC Genome plans to significantly upgrade the iCanSearch test next year, expanding its coverage from the current six cancer types to ten. The upgraded version is expected to offer higher reliability and performance based on clinical specimen data from more than 8,000 individuals, including both healthy subjects and cancer patients.

iCanSearch is a test developed independently by GC Genome that utilizes an artificial intelligence (AI) algorithm and whole genome sequencing (WGS) technology to detect multiple cancer signals from just 10 mL of blood. In addition to specific cancer types, it analyzes atypical signals to identify potential high-risk groups, demonstrating its potential as a "cancer type non-specific early warning system."

The clinical performance of this technology has already been recognized globally, having been published in international journals such as Nature Communications (IF 14.7) and Cancer Research (IF 12.5).

Kichang Seok, CEO of GC Genome, stated, "iCanSearch is evolving beyond a technology-oriented test to one that contributes directly to patient care in real clinical settings. As a company leading the AI-based multi-cancer early diagnosis market, we will continue to develop tests that provide real value and trust to both medical professionals and patients."

This content was produced with the assistance of AI translation services.